PD-1 ligation to its ligands, PD-L1 and PD-L2 expressed on tumor cells or APCs, results in T cell inhibition and immune escape, and its blockade with monoclonal antibodies have yielded excellent clinical outcome (21, 50, 55, 148). This evidence concerns the gene PDCD1LG2 and neoplasm.